HC Wainwright Reaffirms “Buy” Rating for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Monday, Marketbeat Ratings reports. They presently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 200.00% from the stock’s previous close. HC Wainwright also issued estimates for Abeona Therapeutics’ Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.05 EPS and FY2026 earnings at ($0.12) EPS.

A number of other brokerages have also weighed in on ABEO. StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd. Oppenheimer assumed coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Stock Down 2.3 %

Shares of Abeona Therapeutics stock opened at $5.00 on Monday. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $8.45. The company has a market capitalization of $217.36 million, a P/E ratio of -1.86 and a beta of 1.79. The business’s fifty day moving average price is $5.43 and its two-hundred day moving average price is $5.82. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19. As a group, research analysts forecast that Abeona Therapeutics will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC bought a new stake in shares of Abeona Therapeutics in the 3rd quarter worth approximately $84,000. JPMorgan Chase & Co. grew its position in Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 28,606 shares during the last quarter. Western Standard LLC grew its position in Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after buying an additional 110,998 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new position in shares of Abeona Therapeutics in the third quarter valued at $151,000. Finally, XTX Topco Ltd acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at $160,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.